The impact of DR3 microvariation on peptide binding: The combinations of specific DRβ residues critical to binding differ for different peptides

Human Immunology

Volumn 49, Issue 2, 1996, Pages 96-105

  Posch, Phillip E ^b   Hurley, Carolyn Katovich ^a   Geluk, Annemieke ^b   Ottenhoff, Tom H M ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; HEMAGGLUTININ; HLA DR3 ANTIGEN; MYELIN BASIC PROTEIN;

ANIMAL CELL; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; HLA SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION;

EID: 0030248513     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/0198-8859(96)00061-4     Document Type: Article

References (45)

1. 1. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33, 1993.
2. 2. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RC, Strominger JL, Wiley DC: Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215, 1994.
3. 3. Stern LJ, Wiley DC: Antigenic peptide binding by class I and class II histocompatibility proteins. Structure 2:245, 1994.
4. 4. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DAA, Strominger JL: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogenous in size. Nature 358:764, 1992.
5. 5. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27, 1993.
6. 6. Newcomb JR, Cresswell P: Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated αβ dimers. J Immunol 150:499, 1993.
7. 7. Boehncke W-H, Takeshita T, Pendelton CD, Houghton RA, Sadegh-Nasseri S, Racioppi L, Brezofsky JA, Germain RN: The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. J Immunol 150: 331, 1993.
8. 8. Busch R, Hill CM, Hayball JD, Lamb JR, Rothbard JB: Effect of natural polymorphism at residue 86 of the HLA-DR β chain on peptide binding. J Immunol 147:1292, 1991.
9. 9. Demotz S, Barbey C, Corradin G, Amoroso A, Lanzavecchia A: The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur J Immunol 23:425, 1993.
10. 10. Geluk A, van Meijgaarden KE, Janson AAM, Drijfhout JW, Meloen RH, de Vries RRP, Ottenhoff THM: Functional analysis of DR17 (DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. J Immunol 149:2864, 1992.
11. 11. Geluk A, van Meijgaarden KE, Southwood S, Oseroff C, Drijfhout JW, de Vries RRP, Ottenhoff THM, Sette A: HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J Immunol 152:5742, 1994.
12. 12. Geluk A, Fu X-T, van Meijgaarden KE, Jansen YYR, de Vries RRP, Karr RW, Ottenhoff THM: TCR-and peptide contacting residues in the HLA-DR17 (3) β1 chain. Eur J Immunol 24:3241, 1994.
13. 13. Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, Takacs B, Sinigaglia F: Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74:197, 1993.
14. 14. Hill CM, Liu A, Marshall KW, Mayer J, Jorgensen B, Yuan B, Cubbon RM, Nichols EA, Wicker LS, Rothbard JB: Exploration of requirements tor peptide binding to HLA DRB1*0101 and DRB1*0401. J Immunol 152: 2890, 1994.
15. 15. Krieger JI, Karr RW, Grey HM, Yu W-Y, O'Sullivan D, Batovsky L, Zheng Z-L, Colon SM, Gaeta FCA, Sidney J, Albertson M, del Guercio M-F, Chesnut RW, Sette A: Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol 146:2331, 1991.
16. 2-terminal including proline as a stop signal for trimming. J Immunol 151:4732, 1993.
17. 17. Malcherek G, Volker G, Stevanovic S, Rammensee H-G, Jung G, Melms A: Analysis of allele-specific contact sites of natural HLA-DR17 ligands. J Immunol 153:1141, 1994.
18. 18. Marshall KW, Liu AF, Canales J, Perahia B, Jorgensen B, Gantzos RD, Aguilar B, Devaux B, Rothbard JB: Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. J Immunol 152:4946, 1994.
19. 19. Matsushita S, Takahashi K, Motoki M, Komoriya K, Ikagawa S, Nishimura Y: Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: Implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J Exp Med 180:873, 1994.
20. 20. O'Sullivan D, Sidney J, Appella E, Walker L, Phillips L, Colon SM, Miles C, Chesnut RW, Sette A: Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol 145:1799, 1990.
21. 21. O'Sullivan D, Arrhenius T, Sidney J, del Guercio M-F, Albertson M, Wall M, Oseroff C, Southwood S, Colon SM, Gaeta FCA, Sette A: On the interaction of promiscuous antigenic peptides with different DR alleles: Identification of common structural motifs. J Immunol 147: 2663, 1991.
22. 22. Sette A, Sidney J, Oseroff C, del Guercio M-F, Southwood S, Arrhenius T, Powell MF, Colon SM, Gaeta FCA, Grey HM: HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol 151:3163, 1993.
23. 23. Sidney J, Oseroff C, Southwood S, Wall M, Ishioka G, Koning F, Sette A: DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DRβ1 alleles. J Immunol 149:2634, 1992.
24. 24. Vogt AB, Kropshofer H, Kalbacher H, Kalbus M, Rammensee H-G, Coligan JE, Martin R: Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol 153:1665, 1994.
25. 25. Wucherpfennig KW, Sette A, Southwood S, Oseroff C, Matsui M, Strominger JL, Hafler DA: Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 179:279, 1994.
26. 26. Zeliszewski D, Golvano JJ, Gaudebout P, Dorval I, Freidel C, Gebuhrer L, Betuel H, Borras-Cuesta F, Sterkers G: Implication of HLA-DR residues at positions 67, 71, and 86 in interaction between HLA-DR11 and peptide HA 306-320. J Immunol 151:6237, 1993.
27. 27. Posch PE, Araujo HA, Creswell K, Praud C, Johnson AH, Hurley CK: Microvariation creates significant functional differences in the DR3 molecules. Hum Immunol 42:61, 1995.
28. 28. Geluk A, Gloemhoff W, de Vries RRP, Ottenhoff THM: Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Eur J Immunol 22:107, 1992.
29. 29. Geluk A, Elferink DG, Slierendrgt BL, van Meijgaarden KE, de Vries RRP, Ottenhoff THM, Bontrop RE: Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates. J Exp Med 177:979, 1993.
30. 30. Jacobson S, Sekaly RP, Jacobson CL, McFarland HF, Long EO: HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol 63: 1756, 1989.
31. 31. Hickling JK, Fenton CM, Howland K, Marsh SGE, Rothbard JB: Peptides recognized by class I restricted T cells also bind to MHC class II molecules. Int Immunol 2:435, 1990.
32. 32. Asu UM, Taylor M, Dunn D, Fuller TC: Identification of a new HLA-DR3 allele: DRB1*0305. Tissue Antigens 46:405, 1995.
33. 33. Apple RJ, Erlich HA: Two new HLA DRB1 alleles found in African Americans: Implications for balancing selection at positions 57 and 86. Tissue Antigens 40:69, 1992.
34. 34. Zangenberg G, Huang MM, Arnheim N, Erlich H: New HLA-DPB1 alleles generated by interallelic gene conversion detected by analysis of sperm. Nat Genet 4:407, 1995.
35. 35. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F: Precise prediction of major histocompatibility complex class II-peptide interactions based on peptide side chain scanning. J Exp Med 180:2353, 1994.
36. 36. Hurley CK, Steiner N: Differences in peptide binding of DR11 and DR13 microvariants demonstrate the power of minor variation in generating DR functional diversity. Human Immunol 43:101, 1995.
37. 37. Posch PE, Hastings AE, Rosen-Bronson S, Richert JR, Hurley CK: The relative importance of individual DR binding motif positions as defined by peptide anchor analysis of influenza hemagglutinin peptide 306-318 and human myelin basic protein peptide 152-165 binding to several DR molecules: Definition of a common extended DR binding motif. Eur J Immunol (in press).
38. 38. Lamont AG, Powell MF, Colon SM, Miles C, Grey HM, Sette A: The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo. J Immunol 144:2493, 1990.
39. 39. Nelson CA, Petzold SJ, Unanue ER: Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell. Nature 371:250, 1994.
40. 40. Vignali DAA, Strominger JL: Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor. J Exp Med 179:1945, 1994.
41. 41. Manca F, Clarke JA, Miller A, Sercarz EE, Shastri N: A limited region within hen egg-white lysozyme serves as the focus for a diversity of T cell clones. J Immunol 133: 2075, 1984.
42. 42. Schwartz RH, Fox BS, Fraga E, Chen C, Singh B: The T lymphocyte response to cytochrome c: Determination of the minimal peptide size required for stimulation of T cell clones and assessment of the contribution of each residue beyond this size to antigenic potency. J Immunol 135: 2598, 1985.
43. 43. Valmori D, Sabbatini A, Lanzavecchia A, Corradin G, Matricardi PM: Functional analysis of two tetanus toxin universal T cell epitopes in the interaction with DR1101 and DR1104 alleles. J Immunol 152:2921, 1994.
44. 44. Vignali DAA, Urban RJ, Chicz RM, Strominger JL: Minute quantities of a single immunodominant foreign epitope are presented as large nested sets by major histocompatibility complex class II molecules. Eur J Immunol 23:1602, 1993.
45. 45. Parker KC, Bednarek MA, Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163, 1994.